Tigermed
A contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.
Launch date
Market cap
AUD8.0b
Enterprise valuation
AUD8.2b (Public information from Sep 2024)
Share price
HKD27.05 3347.HK
Hangzhou Zhejiang (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 2.8b | 3.2b | 5.2b | 7.1b | 7.4b |
| % growth | - | 14 % | 63 % | 36 % | 4 % |
| EBITDA | 1.0b | 1.3b | 2.1b | 2.4b | 2.6b |
| % EBITDA margin | 36 % | 40 % | 40 % | 34 % | 36 % |
| Profit | 842m | 1.7b | 2.9b | 2.0b | 2.0b |
| % profit margin | 30 % | 55 % | 55 % | 28 % | 27 % |
| R&D budget | 124m | 157m | 212m | 235m | 262m |
| R&D % of revenue | 4 % | 5 % | 4 % | 3 % | 4 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about Tigermed
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
exited
exited
exited
ACQUISITION by Tigermed Oct 2015
